The U.S. Patent and Trademark Office (USPTO) issued Patent Nos. US 12,453,494, US 12,458,257 and US 12,458,258. These patents strengthen the company’s competitive position and intellectual property protection as it advances its CBGM system toward commercialization.

Glucotrack’s device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.